Health AI Central
Share:
Peer-Reviewed Publication
Expert Rev Anticancer Ther2024;24(9):869-880.September 1, 2024Journal Article

Targeted therapies in advanced biliary malignancies: a clinical review.

Udhayvir S Grewal1, Shiva J Gaddam2, Muhammad S Beg3, Timothy J Brown4
1Division of Hematology and Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
2Division of Hematology and Oncology, Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
3Science 37 Inc, Durham, NC, USA.
4Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
PubMed DOI

Abstract

INTRODUCTION: Despite several therapeutic advancements, the proportion of patients with advanced biliary tract cancers (BTC) surviving 5 years from diagnosis remains dismal. The increasing recognition of targetable genetic alterations in BTCs has ushered in a new era in the treatment of these patients. Newer therapeutic agents targeting mutations such as isocitrate dehydrogenase (IDH), fibroblasti…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.